KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

NovoCure (NVCR) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for NovoCure (NVCR) over the last 12 years, with Q3 2025 value amounting to 21.54%.

  • NovoCure's EBITDA Margin fell 8500.0% to 21.54% in Q3 2025 from the same period last year, while for Sep 2025 it was 27.51%, marking a year-over-year decrease of 100.0%. This contributed to the annual value of 28.17% for FY2024, which is 175500.0% up from last year.
  • NovoCure's EBITDA Margin amounted to 21.54% in Q3 2025, which was down 8500.0% from 24.89% recorded in Q2 2025.
  • NovoCure's EBITDA Margin's 5-year high stood at 0.07% during Q1 2021, with a 5-year trough of 49.71% in Q2 2023.
  • For the 5-year period, NovoCure's EBITDA Margin averaged around 24.61%, with its median value being 22.33% (2024).
  • In the last 5 years, NovoCure's EBITDA Margin plummeted by -487200bps in 2023 and then surged by 273800bps in 2024.
  • Over the past 5 years, NovoCure's EBITDA Margin (Quarter) stood at 17.56% in 2021, then tumbled by -91bps to 33.46% in 2022, then decreased by -16bps to 38.66% in 2023, then fell by -2bps to 39.25% in 2024, then soared by 45bps to 21.54% in 2025.
  • Its EBITDA Margin was 21.54% in Q3 2025, compared to 24.89% in Q2 2025 and 24.43% in Q1 2025.